Media coverage about Johnson & Johnson (NYSE:JNJ) has been trending somewhat positive on Tuesday, Accern Sentiment Analysis reports. The research group rates the sentiment of press coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Johnson & Johnson earned a news impact score of 0.18 on Accern’s scale. Accern also assigned media headlines about the company an impact score of 44.9717298309004 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
Here are some of the media headlines that may have impacted Accern’s rankings:
- BRIEF-Zymeworks announces license agreement with Johnson & Johnson Innovation (JNJ) (markets.businessinsider.com)
- Exit by Johnson & Johnson bolsters Medtronic’s insulin pump dominance (m.startribune.com)
- Johnson & Johnson’s (JNJ) Earnings Visibility Makes it Buy – Investorplace.com (investorplace.com)
- Exit by Johnson & Johnson bolsters Medtronic’s insulin pump dominance – Minneapolis Star Tribune (startribune.com)
- JPMorgan Chase Becomes #16 Most Shorted Dow Stock, Replacing Johnson & Johnson (marketnewsvideo.com)
Several research firms have weighed in on JNJ. Credit Suisse Group reiterated a “buy” rating on shares of Johnson & Johnson in a report on Friday, August 4th. Piper Jaffray Companies reiterated a “hold” rating and issued a $120.00 target price on shares of Johnson & Johnson in a report on Wednesday, October 4th. Vetr lowered shares of Johnson & Johnson from a “hold” rating to a “sell” rating and set a $130.49 target price on the stock. in a report on Monday, September 18th. Alembic Global Advisors lowered shares of Johnson & Johnson from a “neutral” rating to an “underweight” rating in a report on Friday, July 21st. Finally, Stifel Nicolaus raised their price objective on shares of Johnson & Johnson from $140.00 to $142.00 and gave the stock a “hold” rating in a report on Wednesday, October 18th. Four equities research analysts have rated the stock with a sell rating, eight have given a hold rating and eleven have assigned a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus target price of $143.70.
Johnson & Johnson (JNJ) opened at $139.50 on Tuesday. Johnson & Johnson has a 12-month low of $109.32 and a 12-month high of $144.35. The company has a market cap of $374,930.72, a PE ratio of 19.55, a PEG ratio of 2.84 and a beta of 0.82. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.32 and a quick ratio of 1.02.
Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, October 17th. The company reported $1.90 EPS for the quarter, beating analysts’ consensus estimates of $1.80 by $0.10. Johnson & Johnson had a net margin of 21.28% and a return on equity of 27.38%. The company had revenue of $19.65 billion during the quarter, compared to the consensus estimate of $19.29 billion. During the same quarter last year, the firm posted $1.68 EPS. The company’s quarterly revenue was up 10.3% on a year-over-year basis. sell-side analysts expect that Johnson & Johnson will post 7.28 earnings per share for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 12th. Stockholders of record on Tuesday, November 28th will be given a $0.84 dividend. This represents a $3.36 dividend on an annualized basis and a dividend yield of 2.41%. The ex-dividend date of this dividend is Monday, November 27th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 58.33%.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.